The association between pre-existing heart failure and cancer incidence: A systematic review and meta-analysis

Data de publicação:

Autores da FMUP

  • Elisabete Lousada Martins Oliveira Bernardes

    Autor

Participantes de fora da FMUP

  • Barbosa, C
  • Cabrita, A
  • Dias, C

Unidades de investigação

Abstract

Introduction and objectives: Cardiovascular diseases (CVD) and cancer are some of the most recognized causes of mortality and morbidity worldwide. Cancer is the second leading cause of death in heart failure (HF) populations. Recent studies have hypothesized that HF might promote the development and progression of cancer. We aim to analyze and discuss the most recent evidence on the relationship between HF and cancer development. Methods: From inception to November 2022, we searched PubMed, Web of Science and ClinicalTrials.gov for relevant articles on patients with HF and a subsequent cancer diagnosis that reported outcomes of overall and site-specific cancer incidence, or mortality. Results: Of 2401 articles identified in our original search, 13 articles met our criteria. Studies reporting risk rate estimates were summarized qualitatively. Studies reporting hazard ratios (HRs), or relative risks were combined in a meta-analysis and revealed that HF was associated with an increased overall cancer incidence with a HR=1.30 (95% CI: 1.04-1.62) compared with individuals without HF. Subgroup analyses by cancer type revealed increased risk for lung cancer (HR=1.87; 95% CI: 1.28--2.73), gastrointestinal cancer (HR=1.22; 95% CI: 1.03-1.45), hematologic cancer (HR=1.60; 95% CI: 1.23-2.08) and female reproductive cancer (HR=1.67; 95% CI: 1.27-2.21). Mortality from cancer was higher in HF patients compared with non-HF subjects with a HR=2.17 (95% CI: 1.23-3.84). Conclusions: Our systematic review and meta-analysis revealed that HF may result in a subsequent increase in cancer incidence as well as in cancer-related mortality. The most common cancer subtypes in HF patients were lung, female reproductive system, and hematologic cancers. Further research is needed to understand this association better and to provide the best (c) 2024 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by

Dados da publicação

ISSN/ISSNe:
0870-2551, 2174-2030

Revista Portuguesa de Cardiologia  Sociedade Portuguesa De Cardiologia

Tipo:
Article
Páginas:
399-414
PubMed:
38583859
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 2

Citações Recebidas na Scopus: 3

Documentos

  • Não há documentos

Métricas

Filiações

Filiações não disponíveis

Keywords

  • adult; aged; all cause mortality; Article; breast cancer; cancer diagnosis; cancer incidence; cancer mortality; cancer patient; cancer risk; female; female genital tract cancer; follow up; gastrointestinal cancer; heart failure; hematologic malignancy; human; lung cancer; male; meta analysis; prostate cancer; quality assessment tool; risk factor; skin cancer; systematic review

Projetos associados

Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION) - NCT05465213

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Estudo Observacional Comercial (EVOLUTION) . AstraZeneca . 2023

Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies (F-CHECK) - NCT05409846

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico (F-CHECK) . Sanofi . 2022

Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population (CarPoS) - NCT05409833

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico (CarPoS) . Pfizer . 2020

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS) - NCT05021835

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Ensaio Clínico Comercial (ZEUS) . Novo Nordisk . 2022

Rastreio da Doença de Fabry em doentes com cardiomiopatias de etiologia desconhecida.

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico( FABRY) . 2022

Serositis in patients with Systemic Lupus Erythematosus: characteristics and associates

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico (Serositis) . 2023

PR Interval in Hypertrophic Cardiomyopathy patients: an easy and worthy risk factor?

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico (Cardiomyopathy) . 2023

High-sensitivity cardiac troponin I as a reliable prognosis biomarker in patients with hypertrophic cardiomyopathy

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico (Troponin I) . 2023

Transthyretin Cardiac Amyloidosis - novel and emerging treatments

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2021

Avaliação do risco de Morte Súbita Cardíaca em doentes com miocardiopatia hipertrófica - Comparação das directrizes Europeias e Americanas

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2022

Insuficiência Cardíaca na Miocardiopatia Hipertrófica: Preditores, Manifestações Clínicas e Tratamento

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2023

Estudo das alterações cardíacas ictais: possível relação com a morte súbita na epilepsia.

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2023

Miocardiopatia dilatada genética - contributo das novas técnicas de diagnóstico molecular e de imagem

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Clínico Académico . 2021

Partilhar a publicação